Loading patent…
AssigneeHadasit Medical Research Services and Development Ltd.
InventorsAbraham Rutenberg, Ronny Uzana, Michal Lotem, Arthur Machlenkin, Galit Eisenberg, Tamar Peretz-Yablonsky, Shoshana Frankenburg, Roni Engelstein
Estimating the term…
The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
A method of treating cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an isolated NTB-A ectodomain, wherein said subject is afflicted with a tumor characterized by lack of NTB-A surface expression, wherein the isolated ectodomain lacks the signal peptide at positions 1-21 of NTB-A.
Dependencies are inferred from the claim text.